## Rodney Baber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5766683/publications.pdf

Version: 2024-02-01

566801 433756 54 971 15 31 citations h-index g-index papers 55 55 55 1090 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology, 2017, 7, 1-12.	1.0	181
2	The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause, 2001, 8, 259-265.	0.8	149
3	A report on 100 cycles of oocyte donation; factors affecting the outcome. Human Reproduction, 1990, 5, 1018-1022.	0.4	108
4	Ongoing ethical issues concerning authorship in biomedical journals: an integrative review. International Journal of Nanomedicine, 2015, 10, 4837.	3.3	63
5	Current barriers and potential strategies to increase the use of longâ€acting reversible contraception (LARC) to reduce the rate of unintended pregnancies in Australia: An expert roundtable discussion. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 206-212.	0.4	56
6	Phytoestrogens and post reproductive health. Maturitas, 2010, 66, 344-349.	1.0	45
7	Transvaginal pulsed Doppler ultrasound assessment of blood flow to the corpus luteum in IVF patients following embryo transfer. BJOG: an International Journal of Obstetrics and Gynaecology, 1988, 95, 1226-1230.	1.1	40
8	Treating menopause — MHT and beyond. Nature Reviews Endocrinology, 2022, 18, 490-502.	4.3	37
9	Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium—a pilot study. Menopause, 2004, 11, 167-175.	0.8	36
10	A randomized placebo-controlled trial on the effectiveness of an herbal formula to alleviate menopausal vasomotor symptoms. Menopause, 2009, 16, 336-344.	0.8	34
11	Therapy for Menopausal Symptoms During and After Treatment for Breast Cancer. Drug Safety, 2005, 28, 1085-1100.	1.4	29
12	Complementary and Hormonal Therapy for Vasomotor Symptom Relief: A Conservative Clinical Approach. Journal of Obstetrics and Gynaecology Canada, 2006, 28, 279-289.	0.3	21
13	Vernix caseosa peritonitis – no longer rare or innocent: a case series. Journal of Medical Case Reports, 2009, 3, 60.	0.4	19
14	Ethical implications of digital images for teaching and learning purposes: an integrative review. Journal of Multidisciplinary Healthcare, 2015, 8, 299.	1.1	17
15	Menopausal symptoms in breast cancer survivors: management update. British Journal of General Practice, 2013, 63, 51-52.	0.7	16
16	An Alternative Regimen of Hormone Replacement Therapy to Improve Patient Compliance. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1989, 29, 66-69.	0.4	15
17	Global Consensus Position Statement on the use of Testosterone Therapy for Women. Maturitas, 2019, 128, 89-93.	1.0	12
18	Hormone replacement therapy: to use or not to use?. Medical Journal of Australia, 2003, 178, 630-633.	0.8	11

#	Article	IF	CITATIONS
19	The hot flush: symptom of menopause or sign of disease?. Climacteric, 2017, 20, 291-292.	1.1	9
20	Early Pregnancy Support in an <i>in vitro</i> Fertilization Program: Does Human Chorionic Gonadotropin Reduce the Miscarriage Rate?. Asia-Oceania Journal of Obstetrics and Gynaecology, 1988, 14, 453-455.	0.0	8
21	Misrepresentation of the risk of ovarian cancer among women using menopausal hormones. Spurious findings in a meta-analysis. Maturitas, 2015, 81, 323-326.	1.0	8
22	An Audit of Oestrogen Implant Hormone Replacement Therapy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1998, 38, 455-460.	0.4	7
23	A brief history of the International Menopause Society. Climacteric, 2017, 20, 85-90.	1.1	7
24	What is scientific truth?. Climacteric, 2017, 20, 83-84.	1.1	5
25	Hormone replacement therapy and the breast. BMJ: British Medical Journal, 2002, 324, 915a-915.	2.4	5
26	A study of pregnancy after endometrial ablation using linked population data. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 286-293.	1.3	4
27	Hormone replacement therapy: to use or not to use?. Medical Journal of Australia, 2003, 178, 630-3.	0.8	4
28	Primary Ovarian Insufficiency. Current Obstetrics and Gynecology Reports, 2014, 3, 223-231.	0.3	3
29	Menopausal hormone therapy—ovarian cancer risk revisited. Nature Reviews Endocrinology, 2015, 11, 322-323.	4.3	3
30	Treating menopausal women: Have we lost our way?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2021, 61, 493-495.	0.4	3
31	Hormone Therapy Use and Risk of Ovarian Cancer. JAMA - Journal of the American Medical Association, 2009, 302, 2203.	3.8	2
32	CHAPTER 1. Phytoestrogens in Health: The Role of Isoflavones. Food and Nutritional Components in Focus, 2012, , 3-13.	0.1	2
33	The Management of Menopausal Symptoms in Women Following Breast Cancer: An Overview. Drugs and Aging, 2018, 35, 699-705.	1.3	2
34	Menopausal hormone therapy and ovarian cancer. Journal of Mid-Life Health, 2015, 6, 101.	0.4	2
35	The Impact of an Instant Pregnancy Test Kit on the Operations of a Major Hospital Casualty Department. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1988, 28, 134-136.	0.4	1
36	Hormone replacement therapy: to use or not to use?. Medical Journal of Australia, 2003, 179, 391-392.	0.8	1

#	Article	IF	Citations
37	On aspirations. Climacteric, 2014, 17, 213-214.	1.1	1
38	The new Climacteric, Climacteric, 2016, 19, 519-519.	1.1	1
39	Teaching the teachers. Climacteric, 2017, 20, 503-504.	1.1	1
40	Advertising in medical journals. Climacteric, 2020, 23, 107-108.	1.1	1
41	Managing the menopause: the question of evidence. Climacteric, 2021, 24, 1-2.	1.1	1
42	1332Endometriosis, assisted reproductive technology and adverse pregnancy outcomes: a population based data linkage study. International Journal of Epidemiology, 2021, 50, .	0.9	1
43	Trophoblast-endometrium co-cultures as a means of assessment of endometrial readiness for implantation. Placenta, 1993, 14, 211-222.	0.7	O
44	The role of oestrogen in cardiovascular disease: benefit or harm?. Medical Journal of Australia, 2000, 172, 347-347.	0.8	0
45	Hip girth as a predictor of abdominal adiposity in postmenopausal women. Nutrition, 2004, 20, 772-777.	1.1	О
46	Climacteric Commentaries. Climacteric, 2012, 15, 398-406.	1.1	0
47	IMS 2014: the new President's view. Climacteric, 2014, 17, 3-3.	1.1	O
48	Dr Alice MacLennan. Climacteric, 2015, 18, 769-769.	1.1	0
49	Are we there yet?. Climacteric, 2016, 19, 520-521.	1.1	O
50	Sex hormones, receptors and modulators. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 391-392.	0.4	0
51	Reply to †Response to Current barriers and potential strategies to increase the use of longâ€acting reversible contraception ( <scp>LARC</scp> )ÂtoÂreduce the rate of unintended pregnanciesÂinÂAustralia: An expert roundtable discussion'. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017. 57. E16-E17.	0.4	0
52	Editor's comment. Climacteric, 2018, 21, 197-197.	1.1	0
53	Letter to the Editor: "Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline― Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1917-e1918.	1.8	0
54	Women's health at midlife and beyond. Climacteric, 2022, 25, 107-108.	1.1	0